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THE FEDERAL LAW OF PRESCRIPTION DRUGSt
The grip of federal authority upon local business opera-
tions was effectively tightened and, indeed, reached a unique
peak with the enactment on October 26, 1951, of the Pre-
scription Drug Amendment to the Federal Food, Drug, and
Cosmetic Act.1
The Prescription Drug Amendment became effective April
26, 1952. It brought under close federal regulation that
indispensable service to local communities traditionally
rendered by pharmacists through the local drug store - the
filling of doctors' prescriptions.
The new law amended Section 503 (b) 2 of the Federal
Food, Drug, and Cosmetic Act to require that drugs shipped
in interstate commerce which are unsafe for lay use shall"
be dispensed by the druggist only upon the prescription of
a licensed practitioner and that such drugs shall bear the
legend "Caution: Federal law prohibits dispensing without
prescription." The amendment further prohibits the refilling
of prescriptions for such unsafe drugs, unless refilling is
authorized in the original prescription or by subsequent
oral order of the prescriber.
The retail druggist or pharmacist who violates these pro-
visions is subject to severe criminal penalties and he may be
enjoined from further violations by a federal district court.3
It is evident that legal counsel for the fifty thousand or
more drug stores in the United States are, by reason of the
Prescription Drug Amendment, going to have an increasing
concern with federal regulation of the activities of their
t This article was submitted for publication on February 15, 1952. [Editor's
note.]
1 52 STAT. 1040 (1938), 21 U.S.C. § 301 et seq. (1946), as amended, 65 STAT.
648 (1952); [19512 U.S.C. Cong. & Adm. Serv. 663. Subsequent citations to this
enactment will be made to Pub. L. No. 215, 82d Cong., 1st Sess. (Oct. 26, 1951).
The Prescription Drug Amendment is quoted in full in the Appendix to this article.
2 52 STAT. 1051 (1938), 21 U.S.C. § 353 (b) (1946).
3 52 STAT. 1043 (1938), 21 U.S.C. § 333 (c) (1946).
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clients and with the laws under which that regulation pro-
ceeds. The fact that even the local druggist's prescription
files themselves will be subject to federal inspection serves
to indicate the intimate character of the control which will
be exercised.4
Of basic importance, but in a more common field of
federal control, is a further requirement of the Prescription
Drug Amendment that the labels of drugs unsafe for lay
use except under medical supervision shall bear, when
shipped in interstate commerce, the official caution state-
ment that federal law prohibits their dispensing without
prescription.
Proposed regulations for the enforcement of the amend-
ment were published in the Federal Register for February
5, 1952. Industry comments on the proposal were invited.
The concepts underlying the prohibitions of the new law
were derived from the so-called Rx or prescription regula-
tions of the Federal Security Administrator 5 which the
amendment superseded when it became effective in April.
But now, for the first time, the Congress has accepted and
enlarged upon those concepts by specific statutory enact-
ment. The doubts of judicial acceptance which have long
dictated a cautious program of enforcement of the Rx regu-
lations will no longer hamper the enforcement agencies
either in areas of interstate or local operation.
As background we ought to examine, before making an
analysis of the provisions of the new amendment, the ques-
tion of the constitutionality of the local regulation provided
4 Cf. SEN. RFx. No. 946, 82d Cong., 1st Sess. 6 (1951), on H.R. 3298 which
became the Prescription Drug Amendment.
5 The Food, Drug, and Cosmetic Act is administered by the Food and Drug
Administration under the supervision of the Federal Security Administrator, who
heads the Federal Security Agency. The Food and Drug Administration is a
constituent unit of that agency. The Rx regulations were promulgated October 9,
1944, and became effective October 10, 1945. 21 CODE FED. REGs. § 1.106 (1949).
They were examined in detail by the writer in Williams, Exemption from the
Requirement of Adequate Directions for Use in the Labeling of Drugs, 2 FooD
DRUo Cos"ranc L.Q. 155 (1947).
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by it, and the reasons for its enactment. The discussion of
reasons for enactment will include a consideration of the
Rx regulations.
I.
Constitutionality of the Prescription
Drug Amendment
Is the control of the business of the local druggist under
the Prescription Drug Amendment a constitutional regula-
tion? The Food, Drug, and Cosmetic Act of 1938,6 as
enacted, provided for limited control of local sales. Section
301(k) ' prohibited the doing of an act resulting in the
misbranding of a food, drug, device, or cosmetic, "if such
act is done while such article is held for sale after shipment
in interstate commerce. . . ." Violators of the prohibition
were subject to criminal penalties.8
United States v. Sullivan I is the principal case involving
this provision. The Government charged, by criminal infor-
mation, that Sullivan, a retail pharmacist in Columbus,
Georgia, had violated Section 301(k) by misbranding cer-
tain sulfathiazole tablets while they were being held for
sale by him after shipment in interstate commerce. Sullivan
had removed some of the tablets from the properly labeled
bottle- in which they were shipped interstate, had placed
them in boxes bearing only the name of the drug, and had
sold them over-the-counter (i.e., without a doctor's prescrip-
tion). The acts of removing, repacking and disposing by
sale were alleged to have caused the misbranding and vio-
lation of Section 301 (k), since the tablets, when sold by
Sullivan, did not bear adequate directions for use as required
6 The Federal Food, Drug, and Cosmetic Act of 1938, 52 STAT. 1040 (1938),
21 U.S.C. § 301 et seq. (1946), succeeded the Food and Drugs Act of 1906, 34
STAT. 768 (1906).
7 52 STAT. 1042 (1938), 21 U.S.C. § 331 (k) (1946).
8 52 STAT. 1051 (1938), 21 U.S.C. § 333 (a) (1946).
9 332 U.S. 689, 68 S. Ct. 331, 92 L. Ed. 297 (1948).
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by clause (1) of Section 502 (f), or adequate warnings as
required by clause (2) of that section.'0
The defendant attacked the constitutionality of Section
301 (k) and maintained that it was inapplicable to the local
acts which allegedly caused the misbranding of the drug.
Sullivan was convicted in the lower court and his convic-
tion was upheld by the Supreme Court of the United States.
The tablets sold by Sullivan had originally been shipped
interstate to a distributor in Georgia who, in turn, had sold
them to Sullivan. Thus, the Supreme Court in this case
found Section 301(k) to be within the power of Congress
even as applied to a second sale after completion of the
interstate shipment.
After the Sullivan decision, Section 301 (k) was amended,
by legislation initiated before the Supreme Court had acted
in that case, making specific the application of Section
301 (k) to sales following the first sale after interstate
shipment."
The so-called seizure section 12 authorizing actions in rem
against offending drugs, was similarly amended to permit
the seizure, pursuant to libels of information filed in federal
court, of "Any article of ... drug . . .that is adulterated
or misbranded when introduced into or while in interstate
10 52 STAT. 1051 (1938), 21 U.S.C. § 352 (1946): "A drug shall be deemed
to be misbranded ... (f) Unless its labeling bears (1) adequate directions for use;
and (2) such adequate warnings against use in those pathological conditions or
by children where its use may be dangerous to health, or against unsafe dosage
or methods or duration of administration or application, in such manner and form,
as are necessary for the protection of users: Provided, That where any require-
ment of clause (1) of this paragraph, as applied to any drug or device, is not
necessary for the protection of the public health, the Administrator shall promul-
gate regulations exempting such drug or device from such requirement."
11 The Miller Amendment, Act of June 24, 1948, 62 STAT. 582 (1948), 21
U.S.C. § 331 (k) (Supp. 1951). As amended, Section 301 (k) reads: "The altera-
tion, mutilation, destruction, obliteration, or removal of the whole or any part
of the labeling of, or the doing of any other act with respect to, a food, drug,
device, or cosmetic, if such act is done while such article is held for sale
(whether or not the first sale) after shipment in interstate commerce and results
in such article being adulterated or misbranded." The extension of the provision
to adulteration is not, of course, relevant to this discussion.
12 52 STAT. 1044 (1938), 21 U.S.C. § 334 (a) (1946).
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commerce or while held for sale (whether or not the first
sale) after shipment in interstate commerce. . . ." The
italicized words were added by the Miller Amendment.13
It is evident, therefore, that even prior to the enactment
of the Prescription Drug Amendment, both Congress and
the Supreme Court had regarded the local field to which
the amendment will extend, as legitimate territory for fed-
eral regulation.
II.
Need for the New Legislation:
The Rx Regulations
The basic need for the Prescription Drug Amendment is
largely traceable to the inadequacy of the so-called Rx
regulations which it superseded and of Section 502 (f)
of -the Act 14 upon which those regulations rely for their
authority.
It is useful, first, to examine the Rx regulations. Their
basic purpose was the same as that of the amendment -
to control the dispensing of drugs which are of such a
nature that they are unsafe except when used under quali-
fied medical supervision.
The proviso to Section 502(f), under which the regula-
tions were promulgated, directs the Federal Security Ad-
ministrator to exempt a drug from clause (1) of that section,
requiring that the labeling of drugs bear adequate directions
for use, where such directions are not necessary for the
protection of the public health.
The Rx regulations establish, in effect, several types of
exemption from the requirement of adequate directions. Our
present interest extends only to the first type, which is
applicable to interstate shipments of drugs which are not
13 62 STAT. 582 (1948), 21 U.S.C. § 334 (a) (Supp. 1951).
14 See note 10 supra.
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recognized by qualified experts as safe or efficacious for use
except under medical supervision.' 5 This exemption is not
optional with the shipper of such drugs. Its effect is that
drugs of the class to which it applies must either be mar-
keted in accordance with the requirements established by
the regulations for so-called exempt drugs or be exposed to
the hazards of legal proceedings. This result follows from
the fact that adequate directions for use by the layman
cannot be written for such drugs. If their labels bear direc-
tions, therefore, they are misbranded under Section 502 (f)
(1), and they may be misbranded under other provisions
of the Act. 6 This means, in general, that, when shipped,
such drugs must bear the prescription legend "Caution: To
be dispensed only by or on the prescription of a physician"
(or "dentist" or "veterinarian," as the case may be), 17 and
that they must not be sold by the retail druggist except upon
a doctor's prescription.
The theory and operation of the regulations is reflected
in the opinion of the United States Court of Appeals for the
Ninth Circuit in the El-O-Pathic Pharmacy case.'" There,
the court directed the issuance of permanent injunctions
against several firms, appellees, who were found to have
misbranded certain sex hormones, principally testosterone,
a male hormone.
The drugs had been shipped to appellees in interstate
commerce labeled with the prescription- legend, as provided
by the Rx regulations. Appellees then relabeled the drugs,
eliminating the legend. The new labels stated that "before
taking testosterone a physician should be consulted," but
they also included a suggested dosage and information as
to how the tablet should be taken.'" The court found appel-
15 21 CODE FED. REGs. § 1.106 (b) (1949).
16 Under Section 403 (a) their labeling may be misleading, 52 STAT. 1047
(1938), 21 U.S.C. § 343 (a) (1946), or under Section 502 (j) they may be
dangerous to health, 52 STAT. 1051 (1938), 21 U.S.C. § 352 (j) (1946).
17 The Prescription Drug Amendment does not apply to veterinary drugs.
18 United States v. El-O-Patbic Pharmacy, 192 F. (2d) 62 (9th Cir. 1951).
19 Id. at 73 n.6.
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lees' collateral advertising, advising "every man and woman
that they can buy these dangerous drugs at their favorite
drugstore," 20 to be entirely inconsistent with the appellees'
avowed intent that the purchasers use the drugs only under
medical supervision. After reciting in detail the expert testi-
mony presented on behalf of the Government as to the
highly dangerous character of testosterone in the hands
of a layman,'the court accepted the Government's argument
that, for such a drug, adequate directions for the layman
could not be written.
The legal position was therefore this: under the Rx
regulations the drugs were "exempt" from the requirement
of adequate directions when shipped in interstate commerce
and when received by appellees, since they bore the pre-
scription legend. Appellees' elimination of the legend re-
moved the exemption and the drugs thereupon became sub-
ject to the requirement that their labels bear adequate direc-
tions for use. Since, however, under the court's decision,
neither the directions prepared by appellees, nor any other,
would satisfy the legal concept of adequacy, the drugs were
misbranded, among other reasons, for failure to bear ade-
quate directions for use.21
This rather curious result exemplifies the character of the
so-called exemption, as defined by the Rx regulations. It is
decidedly not the characteristic "you don't have to" or
relaxing type of exemption, such as, for example, that
(found also in the Rx regulations) for drugs "with respect
to common uses, adequate directions for which are known
by the ordinary individual." 22 It is, instead, a mandatory
20 Id. at 76.
21 Evidently the court was of the opinion that the relabeled drugs were
misbranded under Section 502 (a) because their labeling was misleading, 52 STAT.
1050 (1938), 21 U.S.C. § 352 (a) (1946); because they failed to comply with
Section 502 (f) (2) which requires adequate warning, 52 STAT. 1051 (1938), 21
U.S.C. § 352 (f) (2) (1946); and because, under Section 502 (j), they were
dangerous to health, 52 STAT. 1051 (1938), 21 U.S.C. J 352 (j) (1946).
22 21 CoDn Fa. RF-s. § 1.106 (g) (1949). A similar exemption is contained
in the proposed new Prescription Drug Regulations. Proposed Rule Making,
Federal Security Agency, § 1.106 (h), 17 FED. REan. 1131 (1952).
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exemption. Its essential purpose is not to exempt from a
certain legal obligation, but to impose instead another and
entirely different obligation - that certain drugs be sold
to laymen only on prescription.
Technically, the court of appeals found that appellees had
violated Section 301(k) 23 by so relabeling the drugs as to
misbrand them while they were held for sale after ship-
ment in interstate commerce, and that they had violated
Section 301(a) 24 by reshipping some of the misbranded
drugs in interstate commerce. Under the Rx regulations,
the drugs ceased to be exempt from the requirement of
adequate directions when they were relabeled and disposed
of otherwise than on prescription. We have seen that, there-
fore, since no directions could be written for the drugs
which would be regarded as adequate, no refuge from the
legal stigma of misbranding existed for them.
Thus is illustrated the actual mechanics in the operation
of the Rx regulations. It will be observed that they need
never be pleaded to the court at all since they are merely
collateral to the proceeding. The violation alleged is failure
of the drug to bear adequate directions for use as required
by Section 502 (f) (1), or the violation may be that the
directions are misleading, or that the drug is dangerous to
health when taken in accordance with such directions.25
Significance of Rx Regulations
It would be difficult to dispute the thesis of the Food and
Drug Administration that many potent drugs should be
restricted to use under medical supervision, in the interest
of the public health; and when a court is faced with the
impressive testimony of outstanding experts that a drug is
23 See note 7 supra.
24 52 STAT. 1042 (1938), 21 U.S.C. § 331 (a) (1946). This section prohibits
"the introduction or delivery for introduction into interstate commerce of any
food, drug, device, or cosmetic that is adulterated or misbranded."
25 See note 21 supra.
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highly dangerous for lay use, as was the court of appeals
in the E-O-Pathic Pharmacy case, it is usually reluctant
to disturb the rules and policies of a Government agency
which are supported by such testimony. That the leading
elements of the drug industry have recognized the validity
of the Food and Drug Administration's position, on the
basic prescription drug question, was demonstrated by their
support of the new prescription drug law. The differences
between industry and the Food and Drug Administration
involved not the principle that dangerous drugs should be
restricted to prescription use, but the method by which the
agreed purpose was to be attained.
The Rx regulations are, therefore, not objectionable be-
cause they result in limiting certain drugs to prescription
sale. They have been subjected to the basic criticism, how-
ever, that they are founded upon a tenuous and in some
respects self-contradictory interpretation of the statutory
law. They exemplify a regulatory viewpoint which, perhaps,
is too frequently duplicated by other Government agencies
in the interest of far less worthy causes.
It cannot be said, therefore, that there was a clear statu-
tory mandate for the Rx regulations. On the contrary the
history of the statute furnishes reason to believe that the
language of the statute authorizing exemption from ade-
quate directions for use where such directions are "not
necessary for the protection of the public health" contem-
plated, essentially, situations where the uses of the drug
were so well known that directions were unnecessary to
guide the layman. 6 This would appear to be the normal
and natural interpretation of that language. We can all find
satisfaction, however, in the circumstance that, in the in-
stance of the prescription drug problem, the proper branch
26 See Williams, supra note 5 at 163 et seq. It has been noted, note 22 supra,
that the Rx regulations do contain an exemption of drugs for common uses, for
which adequate directions are known by the ordinary individual, and that this
exemption is retained in the proposed new Prescription Drug Regulations.
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- the legislative - has now acted, with the support of both
Government and industry.
In the El-O-Pathic Pharmacy case the court of appeals
declared, with reference to dangerous drugs: 27
The only adequate instructions for use in such cases would
seem to be a caution that it [the drug] be used only on the
prescription of a physician. . . . The inscription on a label,
"Caution-To be used only by or on the prescription of a physi-
cian," would appear to constitute what is comprised within
"adequate directions for use" according to the intendment of
the law.
The court cited United States v. Sullivan 28 in support of this
position and pointed out that appellees' argument was in
conflict with this view since it urged that "when the Ad-
ministrator exempts a drug from such directions, he has no
authority to do anything more, such as, in this case, requir-
ing, by regulation" the use of the official caution legend.29
Then the court turned to the Government's argument that
the conditional exemption imposed by the Rx regulations is
valid and concluded that the purposes of the Act require it
to sustain that argument. It is hardly necessary to dwell
upon the inconsistency of these two positions assumed, one
after the other, by the court of appeals. How can the Rx
regulations operate to provide an exemption from the re-
quirement of adequate directions if that requirement is, in
fact, met by the use of the caution statement upon which
the regulations insist as a condition of the exemption? If the
court's view is correct it would presumably be unnecessary
to comply with the conditions of. the Rx regulations other
than use of the prescription legend, in order to get the
benefit of the exemption.
Yet this kind of incongruity is hardly surprising where, as
often occurs today, a Government position of dubious valid-
27 United States v. E1-O-Pathic Pharmacy, 192 F. (2d) 62, 74 (9th Cir. 1951).
28 332 U.S. 689, 691, 68 S. Ct. 331, 92 L.Ed. 297 (1948). The Court, per
Justice Black, observed that the official caution statement of the Rx regulations
appeared to constitute adequate directions, since it was required by the regulations.
29 192 F. (2d) at 75.
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ity is urged upon the court, but which the court regards as
reflecting a sound and desirable policy. This viewpoint
demands a degree of sympathy where, as in this case, the
Government agency involved is pressing for an end which
is generally viewed as pro bono publico. But general agree-
ment upon either the philosophy or the particular aims of
Government agencies is by no means always present. In this
quandary judicial legislation is abhorrent and in any case
dangerous when its possible benefits are weighed against its
undemocratic implications.
Inadequacies of Existing Law and Regulations
The House Committee reported: 3
The present law and regulations do not provide a satisfactory
method for determining the drugs which properly fall .within the
prescription class. Furthermore, these matters should be regulated
by specific statutory provisions rather than, as at present, largely
through administrative regulations.
The Committee thought that there was great confusion and
lack of uniformity in the application of the official prescrip-
tion legend, to the disadvantage of the public, and the retail
druggist who might innocently violate the law.31
Moreover, the problem of oral prescriptions and refilling
of prescriptions required specific regulations in the interest
of the public, the retail druggist and the physician. 2 The
old law did not specifically recognize the dispensing
of drugs on oral prescription - a practice which is some-
times unavoidable; and the Food and Drug Administration
has interpreted the statute to prohibit the unauthorized
refilling of any prescription, regardless of the character of
the drug involved. Unauthorized refills of habit-forming
drugs have become of great concern to the Administration.33
30 H.R. R a. No. 700, 82d Cong., 1st Sess. 4 (1951).
31 Id. at 2, 4.
32 The original Senate and House bills were, in fact, confined to these matters.
33 H.R. REP. No. 700, 82d Cong., 1st Sess. 1, 7 (1951).
NOTRE DAME LAWYER
The House Committee proposed to deal with the confu-
sion, which it believed existed in the use of the official
prescription legend, by providing for a list of prescription
drugs. 4 The House bill,35 as reported by the Committee,
contemplated that such a list would be formulated by the
Federal Security Administrator.16 This proposal constituted
such ant explosive issue that it resulted in the defeat of the
Committee bill. The listing provision had been opposed
before the Committee by the American Drug Manufacturers
Association, the Proprietary Association, the American
Pharmaceutical Manufacturers' Association, and the Ameri-
can Pharmaceutical Association. These organizations were
joined by the American Medical Association and the com-
bination delivered the fatal punch. Basically, their objection
was that the listing provision constituted too great an ex-
tension of Government authority over drugs, the industry
and the medical profession. 7
On the other hand, the listing provision was powerfully
supported by the National Association of Retail Druggists.
This organization insisted that, with a list to consult, which
had the force of law and was therefore authoritative, the
druggist would be protected both from dependence upon the
decision of the manufacturer or shipper and from the hazard
of making his own decision, as to whether a particular drug
could legally be sold over-the-counter. In practice, the
manufacturer's labeling was accepted as proper by most
druggists who desired to follow the regulations of the Food
34 At the hearings before both the House and Senate Committees, industry
witnesses, other than those for the National Association of Retail Druggists,
repeatedly insisted that the alleged confusion between prescription and non-
prescription drugs was largely non-existent.
35 H.R. 3298, 92d Cong., 1st Sess. (1951).
36 See note 33 supra.
37 See, for example, the statement of Mr. Charles Wesley Dunn, counsel for
the American Pharmaceutical Manufacturers' Association. Hearings before the
Committee on Interstate and Foreign Commerce, House of Representatives, on
H.R. 3298, 82d Cong., 1st Sess. 81 (1951). Some members of Congress were
strongly influenced, as the House debate demonstrated, by their opposition to the
policies of the incumbent Federal Security Administrator.
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and Drug Administration. We shall see, in discussing the
new legislation itself, that no real substitute was obtained
for the administrative list which was defeated on the floor
of the House of Representatives.
MI.
Analysis of Provisions of Prescription
Drug Amendment
The Prescription Drug Amendment, amended Section
503(b)(1)," provides that unsafe drugs, except narcotics
subject to the Internal Revenue Code,39 shall be dispensed
only (i) upon a written prescription, or (ii) upon an oral
prescription which is reduced promptly to writing and filed
by the pharmacist, or (iii) by refilling the oral or written
prescription, upon authorization of the prescriber. This
authorization may appear in the original written prescription
or may be given by oral order which must promptly be
reduced to writing by the pharmacist.
The drugs so restricted are:
A. Habit forming drugs.4"
B. Dangerous drugs. This category comprises every drug
which, "because of its toxicity or other potentiality for
harmful effect, or the method of its use, or the col-
lateral measures necessary to its use, is not safe for
use except under the supervision of a practitioner
licensed by law to administer such drug."
C. New drugs which are subject to control under Section
505 of the Act,4 1 and which under that section have
38 For convenience the first section of the amendment is referred to herein
in terms of the new Section 503 (b) of the Food, Drug, and Cosmetic Act.
39 52 STAT. 1052, 21 U.S.C. § 353 (b) (1946), as amended, Pub. L. No. 215,
82d Cong., 1st Sess. (Oct. 26, 1951).
40 Defined in Federal Food, Drug, and Cosmetic Act, 52 STAT. 1050 (1938),
21 U.S.C. § 352 (d) (1946). Such drugs include the habit-forming narcotics and
the barbiturates. Under Section 503 (b) of the amendment, habit-forming drugs
and new drugs (Class C) may be removed from the prescription requirements
where such requirements are not necessary for the protection of .the public health.
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been permitted to use the channels of interstate com-
merce only upon the condition that they be used under
the professional supervision of practitioners licensed
to administer them.
The act of dispensing a drug of class A, B, or C, without
prescription or otherwise contrary to these provisions, is an
act which results in the drug being misbranded while held
for sale. Thus Section 301 (k) and the criminal and civil
sanctions of the Act are brought in the amendment. It is
clear, therefore, that the local druggist who fails to observe
the prescription requirement will be subject to those sanc-
tions.
An unsafe drug is also misbranded under paragraph (4)
"if, at any time prior to dispensing, its label fails to bear
the statement 'Caution: Federal law prohibits dispensing
without prescription.'" In this manner the manufacturer
who fails to place the caution or Rx legend upon a drug
before interstate shipment is brought within the area of
civil or criminal enforcement action.
Finally, insofar as this portion of the analysis of the
amendment is concerned, a drug which is not unsafe is mis-
branded under paragraph (4) if, at any time prior to dis-
pensing, its label bears the caution statement. This provision
follows, in spirit at least, the Rx regulations replaced by the
amendment. These regulations did not exempt from the
requirement of adequate directions those non-dangerous
drugs which can be used effectively by the layman with
adequate directions to guide him. The effect was that, under
the regulations, these drugs had to bear directions."
41 52 STAT. 1052 (1938), 21 U.S.C. § 355 (a) (1946). This section provides:
"No person shall introduce or deliver for introduction into interstate commerce
any new drug, unless an application filed pursuant to subsection (b) is effective
with respect to such drugs." Section 201 (p) defines the term "new drug." 52,
STAT. 1041 (1938), 21 U.S.C. § 321 (p) (1946).
42 The proposed new regulations, provide that a drug not subject to the
amendment will not be misbranded under paragraph (4) because it bears, in
addition to "adequate directions," a statement that the user should consult a
physician. Proposed Rule Making, Federal Security Agency, § 1.108 (f), 17 FED.
REGs. 1132 (1952).
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It will be recalled that a principal aim of that segment
of the industry which sponsored the bill as reported by the
House Committee, was to relieve the retail druggist of the
responsibility for deciding whether a given drug must be
limited to prescription sale. The initial effort to achieve this
result by authorizing the Federal Security Administrator
to formulate a list of prescription drugs failed, as has been
noted, on the floor of 'the House of Representatives.
An understanding was reached on this point by the inter-
ested industry groups while the bill was before the Senate.4 3
It is reflected in Section 2 of the new law, which amends
Section 303 (c) of the Act." Under this provision a druggist
who receives in interstate commerce a drug other than one
which is unsafe within the meaning of the Prescription Drug
Amendment is given protection against criminal prosecution
for selling the drug without adequate directions and warn-
ings as required by Section 502 (f), if he uses the directions
and warnings which were on the label of the drug when
he received it and if he does so "in good faith." But this
qualified protection does not extend to unsafe drugs covered
by the amendment.4"
Consequently, the druggist is in the same position as he
was before the amendment, as far as his responsibility for
failure to properly identify unsafe drugs and to restrict them
to sale on prescription is concerned. As a matter of fact, the
Food and Drug Administration has never brought a prose-
cution against a druggist under the circumstances described
in Section 2 of the Prescription Drug Amendment - where
an over-the-counter drug was repackaged and sold with the
43 SEN. Rn P. No. 946, 82d Cong., 1st Sess. 2, 3 (1951). Hearings before the
Subcommittee on Health of the Committee on Labor and Public Welfare, U.S.
Senate, on S. 1186 and H.R. 3298, 82d Cong., 1st Sess. 76 et seq. (1951).
44 52 STAT. 1043 (1938), 21 U.S.C. § 333 (c) (1946).
45 The Senate report emphasizes the fact that the responsibility for proper
labeling of non-prescription drugs is upon the manufacturer, but that the law
offers the druggist ". . . no protection against violations which arise if he sells a
dangerous drug covered by paragraph (1) of the bill without meeting the pre-
scription requirements." SaN. REP. No. 946, 82d Cong., 1st Sess. 7, 10 (1951).
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same directions as those which the manufacturer had placed
on the interstate container, and official doubt has been ex-
pressed that such a prosecution would be authorized by
Section 303 (c) of the statute.4
Most druggists will continue to depend upon the classifi-
cation made by the manufacturer or shipper, unless guid-
ance is furnished by an informal advisory list, without force
of law, issued either by the industry or the Food and Drug
Administration. The interested industry groups have con-
sidered the publication of a list - an action which might
avoid the promulgation of one by the Federal Security
Administrator. This project has apparently been abandoned.
The Food and Drug Administration, however, is committed
to a listing of prescription drugs and will presumably act
if the industry does not do so. Although an advisory list
issued by the Food and Drug Administration would not
have the force of law, it would generally be followed as if
it were a regulation with full legal effect."
Paragraph (2) of amended Section 503 (b) exempts drugs
dispensed on prescription from the misbranding provisions
of Section 502 of the Act with certain important exceptions,
including those provisions under which a drug is deemed to
be misbranded if its labeling is false or misleading,48 if it is
an imitation of, or offered for sale under the name of, an-
other drug,49 or if it is not packaged as prescribed pursuant
to law.5" A specific condition of this exemption is that the
46 See statement of Mr. George Larrick, Deputy Commissioner of Food and
Drugs, Hearings, supra note 43, at 156.
47 If the advisory list were issued as an interpretative regulation pursuant to
Section 701 (a), 52 STAT. 1055 (1938), 21 U.S.C. §371 (a) (1946), and the
pertinent substantive provisions of the Act, it would probably be given some
weight by the courts, as is usual for such regulations, in the absence of indication
by Congress that it should be treated differently.
48 52 STAT. 1050 (1938), 21 U.S.C. § 352 (a) (1946).
49 52 STAT. 1051 (1938), 21 U.S.C. § 352 (i) (2), (3) (1946).
50 52 STAT. 1051 (1938), 21 U.S.C. § 352 (g), (h) (1946). Special provisions
relating to insulin and certain anti-biotics also remain effective for prescription
drugs. 55 STAT. 851 (1941), 21 U.S.C. § 352 (k) (1946); 59 STAT. 463 (1945), 21
U.S.C. §352 (1) (1946).
LAW OF PRESCRIPTION DRUGS
label of the prescription drug must bear, at the time of
dispensing, certain information, essential for the patient,
which is customarily placed on prescription labels, including
any directions for use and cautionary statements contained
in the prescription. 1
This exemption does not apply to a drug dispensed in
violation of the prescription requirements of paragraph (1)
of amended Section 503(b) as if, for example, it were dis-
pensed without a prescription or refilled without authoriza-
tion of the prescriber.
Nor does the exemption apply to a drug dispensed in the
course of the conduct of a business of dispensing drugs pur-
suant to diagnosis by mail. The House bill had included in
the non-exempt class those drugs which were dispensed
"without examination of the patient," but the Senate elimi-
nated that language.2
IV.
The New Prescription Drug Regulations:
Their Basic Character
Circumstances permit only selective consideration of the
proposed new prescription drug regulations published in the
Federal Register for February 5, 1952. The discussion will
be confined chiefly to the basic character of the question of
whether a drug is unsafe within the meaning of the Prescrip-
tion Drug Amendment because it is inefficacious for use
except under medical supervision.
Section 1.106(b), as proposed, provides that
A drug subject to the requirements of section 503(b)(1) of
the act, as amended by 65 STAT. 648 [i.e., a prescription drug],
shall be exempt from section 502(f)(1) [the requirement of
adequate directions] if all of the following conditions are met.
51 The other information required is the name and address of the dispenser,
the serial number and date of the prescription or of its filing, the name of the
prescriber, and, if stated in the prescription, the name of the patient.
52 SEN. REP. No. 946, 82d Cong., 1st Sess. 7 (1951).
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Some of the conditions set forth in the regulation are
based upon the Prescription Drug Amendment - for in-
stance, the condition that the label of an unsafe drug bear
the statement "Caution: Federal law prohibits dispensing
without prescription." Other conditions are not provided
for in the amendment: for example, the condition that the
label bear a statement of "the recommended or average
dose."
Let us examine the legal situation which the proposed
regulations apparently aim to create. If a drug subject to
the Prescription Drug Amendment at any time prior to
dispensing fails to bear the legend "Caution: Federal law
prohibits dispensing without prescription," it is misbranded
under paragraph (4) of the amendment. Under the pro-
posed regulations, since it fails to bear the legend, such a
drug would not be exempt from the requirement of adequate
directions for use under Section 502 (f) (1). By definition,
adequate directions cannot be written for such a drug. This
was pointed out in the El-O-Pathic Pharmacy case. There-
fore, it is misbranded for failure to bear such directions
regardless of what attempt to write them may have been
made, just as it would be under the Rx regulations.
Consider now a drug which complies in all respects with
the Prescription Drug Amendment, but which is not exempt
under the proposed regulations from the requirement of
adequate directions for use because, for example, its label
fails to bear the recommended or average dose and thus
does not meet one of those conditions of the proposed regu-
lations not based upon the Prescription Drug Amendment.
Evidently it is intended that such a drug also shall be re-
garded as misbranded under Section 502(f)(1) for failure
to bear adequate directions for use.
It has been noted that a principal motivation for the new
law was to establish a firm statutory basis for the classifi-
cation and regulation of prescription drugs, in lieu of the
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existing system of Section 502 (f) (1) exemptions. The com-
mittees of Congress which considered the Prescription Drug
Amendment accepted the view of the Food and Drug Ad-
ministration, illustrated in the E-O-Pathic Pharmacy case,
that adequate directions could not be written for the use by
laymen of certain unsafe drugs. The history of the prescrip-
tion legend, as it has developed around the Rx regulations,
features the incompatibility of the legend and directions for
use by laymen.
It is implicit in the Prescription Drug Amendment that an
unsafe drug, when shipped by the manufacturer, shall bear
no directions destined for the layman, and it was patently
contemplated that a drug bearing the legend should, by
reason of that fact, be exempt from Section 502 (f) (1). It
may be questioned, therefore, by what authority the Ad-
ministrator can refuse to grant to a drug in interstate com-
merce an exemption from the requirement of adequate
directions for laymen, upon conditions foreign to the Pre-
scription Drug Amendment which he is not specifically
authorized by any other provision of law to impose. If he
can establish non-statutory conditions, there seems no rea-
son to suppose that he is limited to those named in the
proposed regulations.
The situation brings to mind the decision of the Supreme
Court of the United States in the recent Imitation Jam
case.53 Section 403 (c) of the Act " provides that a food is
misbranded if it is an imitation of another food "unless its
label bears ... the word 'imitation' and, immediately there-
after, the name of the food imitated." This the Supreme
Court regarded as an authorization to market imitation
jam in interstate commerce when labeled as such, refusing
53 62 Cases of Jam v. United States, 340 U.S. 593, 71 S. Ct. 515, 95 L. Ed.
566 (1951).
54 52 STAT. 1047 (1938), 21 U.S.C. § 343 (c) (1946) provides that a food
shall be deemed to be misbranded "... if it is an imitation of another food, unless
its label bears, in type of uniform size and prominence the word 'imitation'
and, immediately thereafter, the name of the food imitated."
NOTRE DAME LAWYER
to accept the Government's argument that it was misbrand-
ed under another provision of the Act, Section 403 (g), on
the ground that it purported to be the "genuine" jam for
which a Government standard had been promulgated. 5 Con-
cededly the Supreme Court did not intend to permit the
marketing of imitations regardless of how they might be
misbranded under other provisions of the statute; but it
evidently thought that Section 403 (c) relieved imitations
labeled as such from a charge of misbranding based, in
effect, upon the fact that they are imitations.
The Prescription Drug Amendment provides that an
unsafe drug shall be misbranded "if at any time prior to
dispensing its label fails to bear" the prescription legend
therein set forth. By reasoning parallel to that of the Su-
preme Court in the Imitation Jam case, it might well be
concluded that the quoted language is an authorization to
market in interstate commerce drugs which bear the pre-
scription legend. We need not suggest that this authoriza-
tion extends to all misbrandings; but it might with some
force be maintained that it surely relieves unsafe drugs from
a charge of misbranding based, in effect, upon the fact that
they are unsafe, and it seems evident that considerations of
safety are the basis for the proposed refusal to exempt drugs
which fail to meet all the conditions of the regulations.
These comments have not dealt with the question of the
desirability of the conditions which would be established by
the proposed regulations. Some of these conditions may be
useful from the standpoint both of Government and indus-
try. It seems indeed unfortunate that, if additional authority
was needed to meet the prescription drug problem, it was
not obtained when the recent amendment was enacted. It
55 62 Cases of jam v. United States, 340 U.S. 593, 600, 71 S. Ct. 515, 95 L.
Ed. 566 (1951). By the terms of the statute, 52 STAT. 1047 (1938), 21 U.S.C.
§ 343 (g) (1946), a food is misbranded which . . . purports to be or is represented
to be a food for which a definition and standard of identity has been prescribed
by regulations as provided by section 401 unless (1) it conforms to such definition
and standard. .. "
LAW OF PRESCRIPTION DRUGS
must be recognized, however, that it is inherent in the
cumbersome character of the legislative process that, at one
time or another during its course, the executive must calcu-
late to a delicate nicety the very least authority needed to
gain the critical core of the legislative proposals. This was
perhaps true of the Prescription Drug Amendment.
Devices and Veterinary Drugs
Sections 1.106(c) and (d) of the proposed regulations
provide exemptions from the requirement of adequate direc-
tions for use for unsafe veterinary drugs and for devices,
for which adequate directions cannot be prepared, upon
conditions roughly similar to those imposed for drugs for
human use. The Prescription Drug Amendment does not,
of course, apply to devices or veterinary drugs. However,
the report of the Senate Committee states: 11
Under the committee bill, drugs intended for use under the
supervision of a veterinarian will not require a prescription,
although it will be possible under section 502 (f) to exempt such
drugs from adequate directions for use if they are to be used by
or under the supervision of a veterinarian.
Presumably this indication of the Committee's attitude is
regarded by the Administrator as sufficient authority to
regulate prescription veterinary drugs as well as prescrip-
tion devices, under Section 502 (f) (1). To the extent that
this regulation fails to include conditions not imposed for
drugs for human beings by the Prescription Drug Amend-
ment, the statement quoted from the Committee Report
doubtless adds strength to the position of the Administrator.
Exemptions for Other Drugs and for
Prescription Chemicals
Subsections (g) and (h) of Section 1.106 provide for
exemptions for new drugs, which are controlled under Sec-
tion 505 of the Act, and for drugs or devices when directions
56 Smrr. REP. No. 946, 82d Cong., 1st Sess. 8 (1951).
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are commonly known, which are required to meet no condi-
tions whatever. Subsections (i) through (1) of that Section
provide for exemptions for inactive ingredients, for diagnos-
tic reagents, for prescription chemicals and other prescrip-
tion components, and for bulk drugs and devices to be pro-
cessed, repacked, or used in the manufacture of another
drug. These exemptions do not raise the problems discussed
above. Their purpose is primarily to relax statutory require-
ments rather than to impose another obligation. Under sub-
sections (i) through (1) the option is given to the manu-
facturer either to label with adequate directions for use,
except in the case of new drugs and unsafe drugs exempt
under subsections (k) and (1), or, by meeting certain con-
ditions, to take advantage of the exemption offered. This
distinguishing characteristic of these provisions, as con-
trasted with the mandatory exemptions for ufhsafe drugs
provided under proposed Section 1.106(b) of the regula-
tions, is emphasized by the language of Section 1.106(n).
Under this section an exemption expires if the exempt drug
or device is disposed of for an unauthorized purpose, and
it is provided: 17
The causing of an exemption to expire shall be considered
an act which results in such drug or device being misbranded
unless it is disposed of for use otherwise than as a drug or
device or unless, in the case of a drug subject to paragraph (i),
(j), (k), or (1) of this section, prior to such disposal, it is re-
labeled to comply with the requirements of section 502(f)(1) of
the act. [Emphasis supplied.]
An unsafe drug exempt under Section 1.106 (k) or (1) can-
not be relabeled with adequate directions pursuant to Sec-
tion 502 (f) (1) because adequate directions cannot be pre-
pared for such a drug. This is, of course, true whether it is
exempt under this section or Section 1.106(b). An over-the-
counter drug which is exempt from adequate directions
57 Proposed Rule Making, Federal Security Agency, § 1.106 (n), 17 Fa.
REG. 1132 (1952).
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under subsections (i), (j), (k), or (1) may, however, be
relabeled as provided in the provision above quoted.
Under this section of the regulations the placing of con-
ditions upon the exemptions does not remove the choice of
the manufacturer either to follow the regulation or to label
the drug with adequate directions or, in the case of unsafe
drugs, to follow the provisions of Section 1.106(b). The
fact that, in some instances, there may be serious practical
difficulties to placing directions on some preparations does
not derogate from this principle. No legal impediment is
raised by the regulations or the administrative interpreta-
tion of the law. Herein lies the contrast between the two
types of exemptions. The elective type seems soundly con-
ceived, in principle, and consistent with the terms of the
statute.
The Question of Efficacy
The Rx regulations, which were superseded by the Pre-
scription Drug Amendment, exempted a drug from the
requirement of adequate directions for use if it was gener-
ally recognized by qualified experts as not being "safe" and
"efficacious" for use except by or under the supervision of a
physician." The prescription drug bill as reported by the
House Committee retained "efficacy" as one of the tests
of a prescription drug." This test was stricken from the
bill on the House floor with the support of at least some of
the majority members of the Committee which had reported
the bill." One member of the majority indicated that, in
his opinion, the word "safe," as used in the bill, "applies to
poisonous drugs, those drugs that are toxic."
In its revision, as we have seen, the Senate Committee
did not reinsert the efficacy test, but confined the scope
58 21 CODE FED. REGs. § 1.106 (b) (1949).
59 H.R. REP. No. 700, 82d Cong., 1st Sess. 1 (1951).
60 97 Cong. Rec. 9544 (August 1, 1951).
61 Statement by Mr. Harris, id. at 9545.
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of the bill to a drug "not safe for use except under the
supervision of a practitioner licensed by law to administer
such drug." This is now paragraph (1) of (B) of amended
Section 503(b). However, its report states: 62
This omission is not intended to mean that the only matter
to be considered in applying the definition is whether or not a
particular drug is poisonous.
The word "safe", as used in the definition, is intended to
have its ordinary meaning. . . . When this language is given
judicial interpretation consistent with the over-all purpose of the
Federal Food, Drug, and Cosmetic Act to protect the public
health it will effectively restrict to prescription sale all drugs
that require professional supervision for their use.
The report mentions quinidine sulfate, used in heart con-
ditions, as an example of non-toxic drugs which are not safe
for self-medication "because their unsupervised use may in-
directly cause injury or death." 63
The interpretations, in the new regulations, of the terms
"other potentiality for harmful effect" under Section 1.108
(a) (3),64 "method of its use" under Section 1.108(a) (4),65
and "collateral measures necessary to its use" in Section
1.108 (a) (5),66 follow the implications of the preceding quo-
tations from the report of the Senate Committee.
The question of whether the efficacy test was to be writ-
ten into the amendment was regarded by the manufacturers
as one of an importance second only to the matter of the
administrative listing of prescription drugs itself. For ex-
62 SEN. REP. No. 946, 82d Cong., 1st Sess. 4 (1951).
63 Ibid.
64 The term "other potentiality for harmful effect" is defined to mean "the
capability of causing harm otherwise than by toxicity," for example, the masking
of symptoms of a progressive disease condition by earache drops with a local
anaesthetic. 17 FED. REG. 1132 (1952).
65 The term "method of its use" means "the route, the procedures, and the
equipment employed in the administration of the drug." 17 FaD. RGG. 1132 (1952).
66 "The term 'collateral measures necessary to its use' includes the professional
skills and laboratory and other technical tests and procedures which the prac-
titioner .. . employs... ." 17 Fan. RaG. 1132 (1952).
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ample, the inclusion of the efficacy test was characterized
as "an obvious step toward socialized medicine by which
the Government will elect to prescribe what medicines we
shall take and under what circumstances," since questions
of efficacy are far less susceptible of objective determination
than are questions of toxicity. 7
It was as a result of the vigorous opposition of the manu-
facturers that the efficacy test was excluded. The quotation
above set forth from the report of the Senate Committee and
the interpretations of statutory terms proposed in the new
regulations indicate, however, that, to a substantial extent,
questions of efficacy are to be included within the bases
upon which the Administrator will determine whether a
particular drug is subject to the Prescription Drug Amend-
ment or is available for over-the-counter sale.
V.
Conclusion
The passage of the Prescription Drug Amendment marks
perhaps the most significant development in federal drug
law since the enactment of the Food, Drug, and Cosmetic
Act of 1938. It may be hoped that this law, and the regula-
tions issued to implement it, will mark the end of the
fundamental disagreement of legal approach which, to a
considerable extent, has characterized the points of view of
important elements of the industry and the Food and Drug
Administration on the prescription drug problem.
The new law is generally recognized as expressive of a
sound public policy. Its penetration into the operations of
local businesses evokes perhaps a tinge of nostalgia for the
old ideals of local autonomy and states' rights; but too often
67 Statement of Mr. George H. Sibley, Vice President, E. R. Squibb & Sons,
Hearings, supra note 43, at 154.
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the states have failed to exercise their rights and have, as
here, found a more powerful and effective federal authority
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AN ACT
To amend sections 303 (c) and 503 (b) of the Federal
Food, Drug, and Cosmetic Act, as amended.
Be it enacted by the Senate and House of Representatives
of the United States of America in Congress assembled, That
subsection (b) of section 503 of the Federal Food, Drug,
and Cosmetic Act, as amended, is amended to read as
follows:
(b) (1) A drug intended for use by man which -
(A) is a habit-forming drug to which section 502 (d) ap-
plies; or
(B) because of its toxicity or other potentiality for harm-
ful effect, or the method of its use, or the collateral measures
necessary to its use, is not safe for use except under the
supervision of a practitioner licensed by law to administer
such drug; or
* Attorney at law, Washington, D.C. Counsel for the National Association of
Frozen Food Packers. B.A., 1928, Henderson-Brown College; LL.B., 1931, Harvard
Law School. Member of the Bars of the District of Columbia, Arkansas and
New York. Formerly Assistant General Counsel, Federal Security Agency. Contri-
butor to the Food Drug Cosmetic Law journal.
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(C) is limited by an effective application under section
505 to use under the professional supervision of a practi-
tioner licensed by law to administer such drug.
shall be dispensed only (i) upon a written prescription of a
practitioner licensed by law to administer such drug, or (ii)
upon an oral prescription of such practitioner which is re-
duced promptly to writing and filed by the pharmacist, or
(iii) by refilling any such written or oral prescription if such
refilling is authorized by the prescriber either in the original
prescription or by oral order which is reduced promptly to
writing and filed by the pharmacist. The act of dispensing
a drug contrary to the provisions of this paragraph shall be
deemed to be an act which results in the drug being mis-
branded while held for sale.
(2) Any drug dispensed by filling or refilling a written
or oral prescription of a practitioner licensed by law to
administer such drug shall be exempt from the requirements
of section 502, except paragraphs (a), (i) (2) and (3),
(k), and (1), and the packaging requirements of paragraphs
(g) and (h), if the drug bears a label containing the name
and address of ,the dispenser, the serial number and date of
the prescription or of its filling, the name of the prescriber,
and, if stated in the prescription, the name of the patient,
and the directions for use and cautionary statements, if any,
contained in such prescription. This exemption shall not
apply to any drug dispensed in the course of the conduct of
a business of dispensing drugs pursuant to diagnosis by mail,
or to a drug dispensed in violation of paragraph (1) of this
subsection.
(3) The Administrator may by regulation remove drugs
subject to section 502 (d) and section 505 from the require-
ments of paragraph (1) of this subsection when such re-
quirements are not necessary for the protection of the public
health.
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(4) A drug which is subject to paragraph (1) of this
subsection shall be deemed to be misbranded if at any time
prior to dispensing its label fails to bear the statement
"Caution: Federal law prohibits dispensing without prescrip-
tion". A drug to which paragraph (1) of this subsection does
not apply shall be deemed to be misbranded if at any time
prior to dispensing its label bears the caution statement
quoted in the preceding sentence.
(5) Nothing in this subsection shall be construed to re-
lieve any person from any requirement prescribed by or
under authority of law with respect to drugs now included
or which may hereafter be included within the classifications
stated in section 3220 of the Internal Revenue Code (26
U.S.C. 3220), or to marihuana as defined in section 3238
(b) of the Internal Revenue Code (26 U.S.C. 3238 (b)).
Sec. 2. Subsection (c) of section 303 of the Federal
Food, Drug, and Cosmetic Act, as amended, is amended by
striking out the period at the end of clause (3) and inserting
in lieu thereof a semicolon and the following: "or (4) for
having violated section 301(b), (c) or (k) by failure to
comply with section 502 (f) in respect to an article received
in interstate commerce to which neither section 503 (a) nor
section 503 (b) (1) is applicable, if the delivery or proffered
delivery was made in good faith and the labeling at the time
thereof contained the same directions for use and warning
statements as were contained in the labeling at the time of
such receipt of such article."
Sec. 3. The provisions of this Act shall take effect six
months after the date of its enactment.
Approved October 26, 1951.
